We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
10
2 active
Approvals
11
Total approvals
Agencies
3
Regulatory bodies
Founded
N/A
Active, not recruiting
2
20.0%
Completed
6
60.0%
Recruiting
EMA
European Medicines Agency
EMC
Electronic Medicines Compendium
1
CIMA_AEMPS
Spanish Agency for Medicines and Medical Devices
4
- Norgine has entered a definitive agreement to acquire Theravia from Mérieux Equity Partners, adding key rare disease treatments SIKLOS® for sickle cell disease and ORPHACOL® for genetic bile disorders to its portfolio. - The acquisition aligns with Norgine's growth strategy, creating a European-based rare disease champion with six core products that will serve as key growth drivers in the medium-to-long term. - This transaction follows Norgine's recent deals with Fennec Pharma for PEDMARQSI® and X4 Pharma for mavorixafor, establishing the company as a partner of choice for commercializing rare and specialty pharmaceuticals in Europe.